PB2352 PROPHYLACTIC PROSTAGLANDIN E1 PREVENT SINUSOIDAL OBSTRUCTION SYNDROME/VENO‐OCCLUSIVE DISEASE OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Background: Prostglandin E1 (PGE1) was used to prevent sinusoidal obstruction/veno‐occlusive disease (SOS/VOD) of the liver after allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. Aims: We evaluated retrospectively that prophylactic using of prostaglandin E1 prevent SOS/VOD of the liver in patients received allogeneic hematopoietic stem cell transplantation. Methods: It was given in continuous intravenous infusion from day ‐8 to day 14 after allogeneic HSCT at a dose of 0.3 micrograms/kg/hour. The patients were studied according to the risk factors for SOS/VOD: diagnosis, intensification of the conditioning and previous liver abnormalities. The diagnosis of SOS/VOD was made on revised diagnosis and severity criteria for SOS/VOD in new classification from the European society for blood and marrow transplantation. Seventy‐eight patients underwent allogeneic HSCT between September 2010 and November 2017 and 71 were treated by PEG1 and seven did not receive it. Results: The median age of included patients was 45‐year‐old (range, 18‐64 year‐old) and the male was 36 patients (46%). The actual incidence of SOS/VOD was 1.3% (one patient) in the PGE1 group and 14.3% (one patient) in the non PGE1 group (P < 0.001). SOS/VOD developed in two of 78 patients (2.6%) with diagnosis day 7 and day 11 after hematopoietic stem cell infusion. of two patients, one had moderate SOS/VOD and one had severe SOS/VOD as new EBMT criteria for severity grading. Two patients who were diagnosed in SOS/VOD were in acute leukemia. Survival at day +100 for Summary/Conclusion: The prophylactic PGE1 treatment may decrease the incidence of SOS/VOD in patients by allogeneic hematopoietic stem cell transplantation.